FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
ATLANTA, April 06, 2016 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota’s CEO & President Joseph Patti, PhD will present a corporate overview and update at the 15th Annual Needham Healthcare Conference on Wednesday, April 13, 2016 at 10:00 a.m. ET in New York.
A live webcast of the presentation can be accessed under “Events and Presentations” in the Investors section of the Company’s website at www.biotapharma.com or at http://wsw.com/webcast/needham76/bota.
A replay of the webcast will be archived for 30 days following the presentation.
About Biota Pharmaceuticals, Inc.
Biota Pharmaceuticals is focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: These include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics currently being evaluated in the Company’s ongoing Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor that has received Fast Track designation by the U.S. FDA, in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.biotapharma.com.
Biota is a registered trademark of Biota Pharmaceuticals, Inc.
Contact: Mark Colonnese Executive Vice President and Chief Financial Officer (678) 221-3381 [email protected] Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
